Search results for "thyrotoxicosis"

showing 5 items of 5 documents

Fetal/Neonatal Thyrotoxicosis in a Newborn From a Hypothyroid Woman With Hashimoto Thyroiditis.

2016

Context: Fetal/neonatal thyrotoxicosis is a rare but potentially life-threatening condition. It is most commonly observed in poorly controlled Graves’ disease during pregnancy. Case Description: Here we describe the first reported case of thyrotoxicosis in a fetus/newborn from a woman with Hashimoto’s thyroiditis and levothyroxine-treated hypothyroidism. Transplacental passage of stimulating TSH-receptor antibodies, measured by a cell-based bioassay, was the underlying mechanism of fetal/neonatal thyrotoxicosis even though the mother had no history of hyperthyroidism. Conclusion: Diagnosis and management of fetal hyperthyroidism can be challenging. TSH receptor antibody testing should be co…

Adultendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)DiseaseHashimoto DiseaseBiochemistryThyroiditisInfant Newborn Diseases03 medical and health sciences0302 clinical medicineEndocrinologyHypothyroidismPregnancyInternal medicinemedicineHumansHashimoto DiseaseFetusPregnancybusiness.industryBiochemistry (medical)Infant NewbornTransplacentalmedicine.diseasePrognosisPregnancy ComplicationsFetal DiseasesEndocrinologyThyrotoxicosis030220 oncology & carcinogenesisFemalebusinesshormones hormone substitutes and hormone antagonistsImmunoglobulins Thyroid-StimulatingThe Journal of clinical endocrinology and metabolism
researchProduct

Two Cases of Thyroid Dysgenesis Caused by Different Novel PAX8 Mutations in the DNA-Binding Region: In Vitro Studies Reveal Different Pathogenic Mech…

2013

Mutations in PAX8, a transcription factor gene, cause thyroid dysgenesis (TD). The extreme variability of the thyroid phenotype makes it difficult to identify individuals harboring PAX8 gene mutations. Here we describe two patients with TD and report two novel PAX8 gene mutations (S54R and R133Q). We performed in vitro studies to functionally characterize these mutations.Using PAX8 expression vectors, we investigated whether the PAX8 mutants localized correctly to the nucleus. To analyze the DNA-binding properties of S54R and R133Q, electrophoretic mobility shift assays were performed. Furthermore, we measured whether the mutant PAX8 proteins were able to activate the thyroglobulin (TG)- an…

MaleEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMutantGene mutationBiologyThyroid dysgenesisPAX8 Transcription Factorchemistry.chemical_compoundEndocrinologyThyroid peroxidaseCongenital HypothyroidismmedicineHumansPaired Box Transcription FactorsChildGeneticsOriginal StudiesThyroid Dysfunction: Hypothyroidism Thyrotoxicosis and Thyroid Function TestsInfant Newbornmedicine.diseasePhenotypePedigreechemistryChild PreschoolThyroid Dysgenesisbiology.proteinFemaleThyroglobulinPAX8DNAThyroid
researchProduct

Treatment of pituitary resistance to thyroid hormone (PRTH) in an 8-year-old boy.

1996

We report on an 8-year-old boy with pituitary resistance to thyroid hormone (PRTH) having a cysteine for arginine substitution at codon 320 in the TR-beta gene who was presented because of thyrotoxicosis. Due to its suppressive effect on the pituitary thyrotropin secretion, treatment with D-thyroxine (D-T4) was started. After a few days, clinical euthyroidism was achieved but thyroid stimulating hormone secretion was not suppressed. Symptoms of thyrotoxicosis relapsed when therapy was interrupted so that therapy with D-T4 was reinstituted and continued to date. Symptoms did not recur, and the psychomotor development proceeded normally. D-T4 should therefore be considered in the treatment of…

MaleThyroid Hormone Resistance Syndromeendocrine systemmedicine.medical_specialtyPituitary glandendocrine system diseasesArginineTreatment outcomeMolecular Sequence DataPathogenesisInternal medicineMedicineHumansAmino Acid SequenceDextrothyroxineThyroid-stimulating hormone secretionChildbusiness.industryThyroidGeneral MedicineD-Thyroxinemedicine.anatomical_structureEndocrinologyThyrotoxicosisTreatment OutcomePediatrics Perinatology and Child HealthMutationbusinessHormoneActa paediatrica (Oslo, Norway : 1992)
researchProduct

Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure?

2017

Resistance to thyroid hormone β (RTHβ) due to homozygous THRB defects is exceptionally rare, with only five kindreds reported worldwide. Cardiac dysfunction, which can be life-threatening, is recognized in the disorder. Here we describe the clinical, metabolic, ophthalmic, and cardiac findings in a 9-year-old boy harboring a biallelic THRB mutation (R243Q), along with biochemical, physiologic, and cardiac responses to carbimazole and triiodothyroacetic acid (TRIAC) therapy. The patient exhibits recognized features (goiter, nonsuppressed thyroid-stimulating hormone levels, upper respiratory tract infections, hyperactivity, low body mass index) of heterozygous RTHβ, with additional characteri…

0301 basic medicineCardiac function curvemedicine.medical_specialtyendocrine systemGoiterendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismCase ReportsCardiovascularthyroidresistance to thyroid hormonehomozygous THRB mutation03 medical and health sciences0302 clinical medicineClinical ResearchInternal medicinemedicine2.1 Biological and endogenous factorsDecompensation2. Zero hungercardiac thyrotoxicosisbusiness.industryThyroidDilated cardiomyopathymedicine.disease3. Good health030104 developmental biologyEndocrinologymedicine.anatomical_structureCarbimazoleHeart Disease6.1 PharmaceuticalsBasal metabolic ratebusinessHormonemedicine.drug
researchProduct

French Endocrine Society Guidance on endocrine side effects of immunotherapy.

2018

The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing…

PD-L1Cancer Researchmedicine.medical_specialtyHypophysitisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmune checkpoint inhibitorsimmune checkpoint inhibitorEndocrine System DiseasesGuidelines and GuidanceEndocrinologyAntineoplastic Agents ImmunologicalPD-1medicineAdrenal insufficiencyEndocrine systemHumansIn patientthyrotoxicosisIntensive care medicinediabetesbusiness.industryCommon Terminology Criteria for Adverse EventsImmunotherapymedicine.diseaseFrequent usehypophysitisOncologyCTLA-4FranceImmunotherapyhypothyroidismbusinessadrenal insufficiencyEndocrine-related cancer
researchProduct